So what happens to the stock options?Forgive me for being naive but I am really curious about what happens to the options that the executve team has at SSS. When their status changes from employee to consultant, do they get to retain the 5,6,7 cent options that they have sitting and waiting for vesting.
Do they still have skin in the game or is it all riding it out for optics and salary now rather than a real cash motivation?
Furthermore...
I know, call me a fool. Many of you will I am sure.
Phase 2B worked.
Phase 2B Placebo worked... don't get me started.
We have not enough money to proceed alone.
Nobody died during the trials so safety won't be a problem for FDA.
Big Drug Companies need patents to grow long term given the patent cliff approaching.
Financing a Phase 3 is chump change for a large company but very hard for a venture company (especially at .05 SP)
We are no longer the best looking car on the lot. That is for sure. We are like a Hurricane Katrina car now with a nice exterior, an odd looking interior but a strange and unidentifiable smell that makes people wonder what the hell is going on beneath the surface. That smell is the smell of confusion brought about by this weird month we have had.
We may never see 50cents again, but do we really just dim the lights and go home? Really?
If Phase 2B failed and we had absolutely nothing to stand on, then I would say fold up the chairs and go home.
It didn't fail. IT DIDN"T FAIL. Reuters said it failed.
Imagine if we were at 50 cents again and had little to no money in the bank (that was our reality) and the Phase 2B came back with a 6.0 on the primary endpoint and a 1 on the placebo.
Champagne corks pop. We all make money, including the executive.
We still can't finance a phase 3 without partnership or dilution in that scenario (although dilution would have hurt a helluva lot less and would have been an easier argument to make).
Or.... call me a fool.